Institutional investors purchased a net $2.0 million shares of ANTH during the quarter ended December 2017 and now own 23.40% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders | 3.07% |
Other institutional | 20.33% |
Individual stakeholders | 0.22% |